Share Class
GB00BJHPHZ49
A high-conviction, bottom-up European Ex-UK Equity strategy
- An investment process seeking profitable companies with attractive long-term prospects, built on robust fundamentals and strong business models
- A high-conviction, low turnover, concentrated portfolio designed to maximise long-term alpha generation
Key documents
Asset Allocation
Equities96.2 %
Other3.8 %
Data as of: 31 Dec 2024.
Risk Indicator
6/7
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
Cumulative Performance 10 YearsCumulative Performance 5 YearsCumulative Performance 3 YearsCumulative Performance 12 Months
+ 88.1 %
0.0 %
+ 54.9 %
+ 20.5 %
+ 16.7 %
To 17/01/2025
Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
-
-
-
-
+ 18.2 %
+ 27.1 %
+ 13.9 %
- 14.8 %
+ 13.9 %
+ 6.8 %
Net Asset Value
1.88 £
Asset Under Management
91 M £
Market
European market
Data as of: 31 Dec 2024.
Data as of: 17 Jan 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
FP Carmignac European Leaders fund performance
Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.Our monthly comments
Data as of: 31 Dec 2024.Fund management team
![[Management Team] [Author] Denham Mark](https://carmignac.imgix.net/uploads/NextImage/0001/18/%5BManagement-Team%5D-Denham-Mark.png?auto=format%2Ccompress&fit=fill&w=3840)
Mark Denham
Head of Equities, Fund Manager
Performance commentary
- During the month of December, the Fund recorded a positive performance relative to its reference indicator.
- Hermes has been the fund's top performer this month, driven by sell-side analysts' positive outlook on its resilient business model and high brand desirability.
- Galderma, a recent addition to our portfolio, has also contributed to the Fund's performance. The company is poised to benefit from the early success of its newly approved atopic dermatitis treatment in the US.
- Our biggest detractors this month has been Novo Nordisk whose shares experienced a significant decline on December 20th following disappointing results from tests of its latest obesity drug, CagriSema.
- Despite this setback, CagriSema remains a valuable addition to Novo Nordisk's obesity product range and competes directly with Eli Lilly’s Zepbound
- Having no exposure to Communication Services and Energy sectors has been supportive during the month.
Outlook strategy
- During the month, our portfolio remained relatively stable without any major changes.
- We decided to take some profits in a few names that have performed well recently, particularly our Financials holdings such as Euronext and Deutsche Borse.
- On the other hand, we took advantage of the significant drop to increase our position in Novo Nordisk as our conviction didn’t significantly change.
- The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
- We stick to our process of focusing on profitable companies with high returns on capital, reinvesting for growth and maintain our focus on stocks and sectors with strong visibility on sales and profits.
Performance Overview
Data as of: 17 Jan 2025.Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 21/01/2025
FP Carmignac European Leaders Portfolio overview
Below is an overview of the composition of the portfolio.Geographical Breakdown
Data as of: 31 Dec 2024.| Europe | 100.0 % |
| Total % Equities | 100.0 % |
Europe100.0 %
 France | 24.7 % |
 Germany | 22.4 % |
 Netherlands | 14.0 % |
 Denmark | 13.8 % |
 Switzerland | 13.7 % |
 Sweden | 5.6 % |
 Ireland | 2.8 % |
 Spain | 1.6 % |
 Italy | 1.5 % |
Key figures
Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.Exposure Data
Data as of: 31 Dec 2024.Equity Investment Weight96.2 %
Net Equity Exposure96.2 %
Number of Equity Issuers35
Active Share78.2 %
The strategy in a nutshell
Discover the Fund’s main features and benefits through the words of the Fund Manager.Fund Management Team
Mark Denham
Head of Equities, Fund Manager
In our approach to European equities, we focus on sustainable high-quality companies which demonstrate high levels of profitability while favoring profits reinvestment over profits distribution to grow the business for the future.
Did you enjoy the fund page?
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Market environment